- Report
- June 2025
- 150 Pages
Global
From €2548EUR$2,699USD£2,127GBP
- Report
- June 2025
- 150 Pages
Global
From €2548EUR$2,699USD£2,127GBP
- Report
- April 2023
- 160 Pages
Global
From €4673EUR$4,949USD£3,901GBP
- Report
- April 2023
- 147 Pages
Global
From €4673EUR$4,949USD£3,901GBP
- Report
- May 2024
- 137 Pages
Global
From €3776EUR$3,999USD£3,152GBP
- Report
- May 2025
- 110 Pages
Global
From €4485EUR$4,750USD£3,744GBP
- Report
- August 2025
- 150 Pages
Global
From €4580EUR$4,850USD£3,823GBP
- Report
- November 2024
- 150 Pages
Global
From €4580EUR$4,850USD£3,823GBP
- Report
- July 2024
- 200 Pages
Global
From €4673EUR$4,949USD£3,901GBP
- Report
- October 2025
- 160 Pages
Global
From €2984EUR$3,160USD£2,491GBP
€3730EUR$3,950USD£3,114GBP
- Report
- October 2025
- 160 Pages
Global
From €2984EUR$3,160USD£2,491GBP
€3730EUR$3,950USD£3,114GBP
- Report
- October 2025
- 160 Pages
Global
From €2984EUR$3,160USD£2,491GBP
€3730EUR$3,950USD£3,114GBP
- Report
- October 2025
- 160 Pages
Global
From €2984EUR$3,160USD£2,491GBP
€3730EUR$3,950USD£3,114GBP
- Report
- April 2023
- 326 Pages
Global
From €3399EUR$3,600USD£2,838GBP
- Report
- September 2025
- 112 Pages
Global
From €3500EUR$3,971USD£3,024GBP
- Report
- March 2026
- 80 Pages
From €3258EUR$3,450USD£2,719GBP
- Report
- September 2025
- 140 Pages
Global
From €4580EUR$4,850USD£3,823GBP
- Report
- January 2024
- 113 Pages
United States
€3305EUR$3,500USD£2,759GBP
- Report
- March 2023
- 30 Pages
Global
€11567EUR$12,250USD£9,656GBP
- Report
- October 2022
- 270 Pages
Global
From €3541EUR$3,750USD£2,956GBP

Infliximab is a monoclonal antibody used to treat a variety of immune disorders, including Crohn's disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, and rheumatoid arthritis. It works by blocking the action of tumor necrosis factor (TNF), a protein that plays a role in inflammation. Infliximab is administered intravenously and is usually given in combination with other medications. It is also used to treat certain types of eye inflammation and to prevent organ rejection in transplant patients.
Infliximab is a biologic drug, meaning it is derived from living cells. It is produced by a number of pharmaceutical companies, including Merck, Pfizer, and Janssen. It is available in both brand-name and generic forms.
The companies in the Infliximab market include Merck, Pfizer, Janssen, Celltrion, Hospira, and Sandoz. Show Less Read more